Abstract
Background
Inhibition of cholesteryl ester transfer protein (CETP) has been shown to have a substantial effect on plasma lipoprotein levels. We investigated whether torcetrapib, a potent CETP inhibitor, might reduce major cardiovascular events. The trial was terminated prematurely because of an increased risk of death and cardiac events in patients receiving torcetrapib.Methods
We conducted a randomized, double-blind study involving 15,067 patients at high cardiovascular risk. The patients received either torcetrapib plus atorvastatin or atorvastatin alone. The primary outcome was the time to the first major cardiovascular event, which was defined as death from coronary heart disease, nonfatal myocardial infarction, stroke, or hospitalization for unstable angina.Results
At 12 months in patients who received torcetrapib, there was an increase of 72.1% in high-density lipoprotein cholesterol and a decrease of 24.9% in low-density lipoprotein cholesterol, as compared with baseline (P<0.001 for both comparisons), in addition to an increase of 5.4 mm Hg in systolic blood pressure, a decrease in serum potassium, and increases in serum sodium, bicarbonate, and aldosterone (P<0.001 for all comparisons). There was also an increased risk of cardiovascular events (hazard ratio, 1.25; 95% confidence interval [CI], 1.09 to 1.44; P=0.001) and death from any cause (hazard ratio, 1.58; 95% CI, 1.14 to 2.19; P=0.006). Post hoc analyses showed an increased risk of death in patients treated with torcetrapib whose reduction in potassium or increase in bicarbonate was greater than the median change.Conclusions
Torcetrapib therapy resulted in an increased risk of mortality and morbidity of unknown mechanism. Although there was evidence of an off-target effect of torcetrapib, we cannot rule out adverse effects related to CETP inhibition. (ClinicalTrials.gov number, NCT00134264 [ClinicalTrials.gov].).References
Articles referenced by this article (15)
HDL as a target in the treatment of atherosclerotic cardiovascular disease.
Nat Rev Drug Discov, (3):193-205 2005
MED: 15738977
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Circulation, (1):8-15 1989
MED: 2642759
Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease.
Pharmacol Ther, (3):893-908 2006
MED: 16574234
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.
N Engl J Med, (13):1301-1310 2007
MED: 17898099
Pros and cons of inhibiting cholesteryl ester transfer protein.
Curr Opin Lipidol, (6):589-596 2000
MED: 11086331
Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis.
Arterioscler Thromb Vasc Biol, (2):160-167 2003
MED: 12588754
Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.
J Am Coll Cardiol, (3):492-499 2006
MED: 16458126
Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits.
J Lipid Res, (6):1263-1272 2007
MED: 17325387
Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.
N Engl J Med, (15):1505-1515 2004
MED: 15071125
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.
J Am Coll Cardiol, (9):1782-1790 2006
MED: 17084250
Show 5 more references (10 of 15)
Citations & impact
Impact metrics
Citations of article over time
Alternative metrics
Discover the attention surrounding your research
https://www.altmetric.com/details/101816098
Article citations
Very high high-density lipoprotein cholesterol may be associated with higher risk of cognitive impairment in older adults.
Nutr J, 23(1):79, 17 Jul 2024
Cited by: 0 articles | PMID: 39020341 | PMCID: PMC11253464
Associations of HDL-C and ApoA-I with Mortality Risk in PCI Patients Across Different hsCRP Levels.
J Inflamm Res, 17:4345-4359, 04 Jul 2024
Cited by: 0 articles | PMID: 38979437 | PMCID: PMC11229981
Comparing the effects of CETP in East Asian and European ancestries: a Mendelian randomization study.
Nat Commun, 15(1):5302, 21 Jun 2024
Cited by: 0 articles | PMID: 38906890 | PMCID: PMC11192935
Imbalance of APOB Lipoproteins and Large HDL in Type 1 Diabetes Drives Atherosclerosis.
Circ Res, 135(2):335-349, 03 Jun 2024
Cited by: 0 articles | PMID: 38828596 | PMCID: PMC11223987
Cholesteryl Ester Transfer Protein Inhibitors and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis.
J Cardiovasc Dev Dis, 11(5):152, 16 May 2024
Cited by: 0 articles | PMID: 38786974 | PMCID: PMC11122262
Review Free full text in Europe PMC
Go to all (1,808) article citations
Other citations
Data
Data behind the article
This data has been text mined from the article, or deposited into data resources.
Clinical Trials
- (1 citation) ClinicalTrials.gov - NCT00134264
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Effect of torcetrapib on the progression of coronary atherosclerosis.
N Engl J Med, 356(13):1304-1316, 26 Mar 2007
Cited by: 589 articles | PMID: 17387129
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
N Engl J Med, 356(16):1620-1630, 26 Mar 2007
Cited by: 391 articles | PMID: 17387131
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.
J Am Coll Cardiol, 48(9):1782-1790, 01 Nov 2006
Cited by: 97 articles | PMID: 17084250
On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
Drugs, 72(4):491-507, 01 Mar 2012
Cited by: 29 articles | PMID: 22356288
Review
Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?
Cardiol Clin, 26(4):537-546, 01 Nov 2008
Cited by: 16 articles | PMID: 18929230
Review